---
title: "Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | FENC Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285531590.md"
description: "Fennec Pharmaceuticals Inc. will report its first quarter 2026 financial results on May 14, 2026, before U.S. market opening. A conference call and webcast will follow at 8:30 a.m. ET to discuss the results. Fennec focuses on reducing ototoxicity in cancer patients with its FDA-approved drug, PEDMARK, and has secured licensing agreements for its commercialization in various regions. For more details, visit their website or follow them on LinkedIn."
datetime: "2026-05-07T02:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285531590.md)
  - [en](https://longbridge.com/en/news/285531590.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285531590.md)
generator: "portal-rs"
---

# Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026 | FENC Stock News

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

**Conference Call & Webcast Detail:**

**Date:** Thursday, May 14, 2026  
**Time:** 8:30 a.m. Eastern Time  
**Webcast Link:** https://edge.media-server.com/mmc/p/2iptdco4  
**Participant Link:** https://register-conf.media-server.com/register/BIaa4b518aeb974d02873eccf8f56d92f3

To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.

**About Fennec Pharmaceuticals**  
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.

PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

For more information, please visit www.fennecpharma.com and follow on LinkedIn.

**For further information, please contact:**

**Investors:**  
Robert Andrade  
Chief Financial Officer  
Fennec Pharmaceuticals Inc.  
+1 919-246-5299

**Corporate and Media:**  
Lindsay Rocco  
Elixir Health Public Relations  
+1 862-596-1304  
lrocco@elixirhealthpr.com

### Related Stocks

- [FENC.US](https://longbridge.com/en/quote/FENC.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention](https://longbridge.com/en/news/296143499.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Fennec Pharmaceuticals Q2 sales rise on PEDMARK demand](https://longbridge.com/en/news/295527022.md)
- [Fennec Pharmaceuticals former director Rosty Raykov disposes of 10,000 common shares worth $95,800](https://longbridge.com/en/news/294863436.md)
- [FENC: Q2 revenue up 78% year-over-year, with record enrollments and strong growth momentum](https://longbridge.com/en/news/295552808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**